[Form 4] Helix Acquisition Corp. II Insider Trading Activity

Rhea-AI Filing Summary

Frank McCormick, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a stock option to purchase 91,076 shares of common stock with an exercise price of $9.59 per share. The option was reported with a transaction date of 08/26/2025 and an expiration date of 08/25/2035. Vesting is governed by a schedule that begins on a Vesting Commencement Date of 08/11/2025: a fractional portion vests on the date an S-8 registration is filed and becomes effective, then 1/48th vests monthly thereafter until fully vested on the fourth anniversary, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

Positive

• Director alignment with shareholders through a time-based stock option grant tied to service
• Clear vesting schedule including initial vesting upon S-8 effectiveness and monthly vesting thereafter until full vesting

Negative

• Potential future dilution if and when the 91,076 options are exercised

Insights

Financial Analyst

TL;DR: Director option grant of 91,076 shares at $9.59, ten-year term, time-based vesting tied to S-8 registration.

The reported grant is a non-derivative stock option covering 91,076 shares with a $9.59 exercise price and a ten-year contractual life to 08/25/2035. Vesting requires an initial pro rata vest upon effectiveness of an S-8 registration and monthly vesting thereafter through the fourth anniversary of the 08/11/2025 vesting commencement date, subject to continued service. For investors, this is a typical equity-based compensation mechanism aligning a directors incentives with shareholder value over multi-year horizons; it does not itself change outstanding share count until exercised.

Corporate Governance Expert

TL;DR: Time-based director award with S-8 filing condition; standard governance practice but requires monitoring of future filings.

The award structure conditions initial vesting on the effectiveness of a Form S-8 registration statement, which is explicitly referenced in the filing. That condition and the multi-year monthly vesting schedule are disclosed clearly and link continued vesting to the reporting persons continuous service. Governance stakeholders should note the contractual vesting triggers and the potential for future filing activity (S-8) to accelerate vesting milestones, as described in the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		91,076		(1)	08/25/2035	Common Stock	91,076	$0	91,076	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 and which company is affected (ticker)?

The reporting person is Frank McCormick and the issuer is BridgeBio Oncology Therapeutics, Inc. (BBOT).

What security and amount were reported on the Form 4?

A stock option to purchase 91,076 shares of common stock was reported.

What is the exercise price and term of the option?

The exercise price is $9.59 per share and the option expires on 08/25/2035.

When does vesting begin and how is it scheduled?

Vesting commencement date is 08/11/2025; a fractional portion vests on the effective date of an S-8 registration and then 1/48th vests monthly until full vesting on the fourth anniversary, subject to continuous service.

When was the transaction and when was the Form 4 signed?

The transaction date is 08/26/2025 and the Form 4 was signed by an attorney-in-fact on 08/28/2025.